Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
The prevalence of abnormal liver tests in people hospitalized with COVID-19 is higher than previously found.
Drugs used for decades to treat malaria may help people with the new coronavirus, but clinical trials are needed.
The protease inhibitor combination did not work significantly better than supportive care, though those treated earlier might benefit.
Neither age nor body weight were significantly associated with type 2 diabetes among older people with HIV in a recent study.
In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.
By year’s end, a new crop of interferon-free hepatitis C combination therapies will likely hit the market.
The FDA has approved revisions to the label of the antiretroviral Kaletra (lopinavir/ritonavir) in order to include new information on...
Victrelis (boceprevir), Merck’s hepatitis C virus (HCV) protease inhibitor, should not be combined with the following Norvir (ritonavir)...
The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)-boosted p...
Vertex Pharmaceuticals? hepatitis C virus (HCV) protease inhibitor telaprevir interacts to varying degrees with commonly used HIV antiretrovir...
People taking once-daily Norvir (ritonavir)-boosted Prezista (darunavir) monotherapy were able to maintain control over HIV for 96 week...
People coinfected with HIV and hepatitis C virus (HCV) who receive Viramune (nevirapine) may respond better to pegylated interferon/ribavirin...
The U.S. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents has come nearly full circle...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.